6105-75-5

Usage

Uses

Used in Epoxy Resin Industry:
2-Methyl-1-morpholino-2-propanamine is used as a curing agent for improving the durability and performance of epoxy resins. It is instrumental in making these resins more resistant to heat, chemicals, and mechanical stress, which is crucial for various industrial applications.
Used in Waterborne Epoxy Coatings and Adhesives:
In the coatings and adhesives sector, 2-Methyl-1-morpholino-2-propanamine is utilized as a hardener to formulate waterborne epoxy systems. Its use ensures that the coatings and adhesives have enhanced properties, such as improved adhesion and resistance to environmental factors.
Used in High-Performance Composites:
2-Methyl-1-morpholino-2-propanamine is employed as a component in the production of high-performance composites. Its role in these materials is to contribute to their overall strength and resilience, making them suitable for applications that demand superior mechanical performance.
Used in Electrical Insulating Materials:
This chemical compound is also used in the formulation of electrical insulating materials. Its contribution to the insulation properties of these materials is vital for ensuring the safety and reliability of electrical systems.
Used in Pharmaceutical Industry:
2-Methyl-1-morpholino-2-propanamine serves as a precursor in the synthesis of various drugs within the pharmaceutical industry. Its role in drug development is significant, as it can be a building block for creating new medicinal compounds.
It is important to handle 2-Methyl-1-morpholino-2-propanamine with care due to its potential to cause irritation to the skin, eyes, and respiratory system. Proper safety measures should be taken during its use to minimize any adverse effects.

InChI:InChI=1/C8H18N2O/c1-8(2,9)7-10-3-5-11-6-4-10/h3-7,9H2,1-2H3

Upstream product

• 110-91-8 morpholine 
• 2658-24-4 2,2-dimethylaziridine 
• 33453-98-4 4-(2-methyl-2-nitropropyl)morpholine 

Downstream Products

• 931126-97-5 N-(2-methyl-1-morpholinopropan-2-yl)-2-(pyridin-3-ylmethylthio)benzamide 
• 1265633-81-5 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-N-(2-methyl-1-morpholinopropan-2-yl)-1H-pyrazole-3-carboxamide 

Relevant academic research and scientific papers

Polycyclic derivatives and preparation thereof

The invention discloses compounds shown as a formula (I) and a formula (II) and stereoisomers, pharmaceutically acceptable salts, solvates, hydrates, N-oxides and prodrugs thereof, pharmaceutical compositions and preparation methods of the compounds and t

NOVEL BETULINIC SUBSTITUTED AMIDE DERIVATIVES AS HIV INHIBITORS

The present invention relates to novel betulinic substituted amide compounds of formula (I); and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, X, Y, Z1, Z2, Z3 and are Formula (II) as defined herein. The invention novel betulinic substituted amide derivatives, related compounds, and pharmaceutical compositions useful for the therapeutic treatment of viral diseases and particularly HIV mediated diseases.

COMBINATIONS FOR THE TREATMENT OF DISEASES INVOLVING CELL PROLIFERATION

The present invention relates to a pharmaceutical composition for the treatment of diseases which involve cell proliferation. The invention also relates to a method for the treatment of said diseases, comprising co-administration of a compound 1 of Formula (I) wherein the groups L, R1, R2, R3, R4 and R5 have the meanings given in the claims and specification, optionally in form of its tautomers, racemates, enantiomers, diastereomers and the mixtures thereof and optionally in form of the pharmacologically acceptable acid addition salts, solvates, hydrates, polymorphs, physiologically functional derivatives or prodrugs thereof, and of an effective amount of an active compound 2 and/or co-treatment with radiation therapy, in a ratio which provides an additive and synergistic effect, and to the combined use of a compound 1 of Formula (I) and of an effective amount of an active compound 2 and/or radiotherapy for the manufacture of corresponding pharmaceutical combination preparations.

DIHYDROPTERIDINONES FOR THE TREATMENT OF CANCER DISEASES

The present invention relates to the use of a compound of general Formula (1), optionally in form of its tautomers, racemates, enantiomers, diastereomers and the mixtures thereof and optionally in form of the pharmacologically acceptable acid addition salts, solvates, hydrates, polymorphs, physiologically functional derivatives or prodrugs thereof, for the preparation of a pharmaceutical composition for the treatment of diseases characterized by abnormal cell proliferation in a human or non-human mammalian body by inhibition of polo like kinases as mitotic regulators.

Storage stable perfusion solution for dihydropteridinones

Disclosed are storage stable aqueous infusible or injectable solutions containing an active substance of general formula (I) wherein the groups L, R1, R2, R3, R4 and R5 have the meanings given in the claims and in the specification, and an amount of a physiologically acceptable acid or mixture of acids sufficient to dissolve the active substance and act as a stabiliser, optionally together with other formulating excipients suitable for parenteral administration, and a process for preparing the infusible or injectable solutions according to the invention.

PI3 KINASES

The invention relates to the novel compounds of formula (1), which, due to their pharmaceutical effect as PI3 kinase modulators, are suitable for use in the therapy and treatment of inflammatory or allergic diseases. Examples of these diseases are inflammatory and allergic respiratory diseases, inflammatory diseases of the gastro-intestinal system and of the locomotor apparatus, inflammatory and allergic skin diseases, inflammatory ophthalmic diseases, diseases of the nasal mucosa, inflammatory or allergic autoimmune reactive conditions, or renal inflammations.

New dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions

The present invention relates to new dihydropteridinones of general formula (I) wherein the groups L and R1- R5 have the meanings given in the claims and specification, the isomers thereof, processes for preparing these dihydropterid

DIHYDROPTERIDINONES, METHOD FOR THE PRODUCTION AND USE THEREOF IN THE FORM OF DRUGS

The invention relates to novel dihydropteridinones of general formula (I), wherein rests L, R1-R5 have the significance indicated in claims and a specification, in the isomers thereof, in a method for producing and using said dihydropteridinones in the form of drugs.